Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Nearly 20,000 medical professionals ... Annual Meeting & Clinical Lab Expo in ... never-before-seen breakthroughs in diagnostic research and technology that will ... As of Wednesday, July 30, more than ... Meeting & Clinical Lab Expo, with more than 10,000 ...
(Date:7/31/2014)... Hopkins have mapped the sound-processing part of the mouse ... forest and the trees in view. Their imaging technique ... activity within mice, and it enabled the team to ... each other. The results, which represent a step toward ... online July 31 the journal Neuron . , ...
(Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Women with Endometriosis -, PHOENIX and BRITISH ... and Medical Center, part of Catholic Healthcare,West, one ... with 42 hospitals,in Arizona, California and Nevada and ... IXS; http://www.ixsbio.com ), a drug,development company commercializing ...
... NORRITON, Pa., Sept. 19 Tengion Inc., a ... of,neo-organs and neo-tissues, today announced that it was ... venture capital-backed innovation and,success at the 35th Anniversary ... Sherrill Neff, Partner at Quaker BioVentures -- a,venture ...
... HARBIN, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... of China ("PRC"), announced today that it,has successfully ... Europeenne (CE) certification, or CE mark, which indicates ...
Cached Biology Technology:St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership 2St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership 3Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3
(Date:8/1/2014)... IN August 1, 2014 The Journal of ... Article and Best Great Educational Material (GEM) awards, which ... Behavior (SNEB) annual conference, "Nutrition Education Impact: Local to ... 2014. These annual awards recognize the authors of ... in JNEB, as judged by members of the JNEB ...
(Date:8/1/2014)... , Aug. 1, 2014  LiveScan Service Provider Binary Biometrics ... team. As a result, Binary Biometrics will improve its mobile service capabilities and ... Volusia County and service several new cities such as, but ... , DeLand , Deltona , ... , New Smyrna Beach , Oak Hill ...
(Date:7/31/2014)... study of bigeye tuna movements in the northwestern Atlantic ... Pelagics Research Center at the University of Massachusetts Amherst, ... wide geographical range with pronounced north-south movements from Georges ... high-use area off Cape Hatteras southwest of Bermuda for ... approach to study one of the most important commercial ...
Breaking Biology News(10 mins):Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3
... Studies has received a $42 million gift-the largest in ... Medicine (HCGM), a research center dedicated to decoding the ... The award, from the Leona M. and Harry ... paves the way to new therapies for chronic illnesses ...
... DIEGO , Jan. 23, 2013 Celladon ... and development of innovative treatments for cardiovascular diseases, ... Trademark Office (USPTO) issued a notice of allowance ... that cover methods for identifying compounds that modulate ...
... water bottles, food containers, and baby products had a ... used to make their merchandise, an organic compound called ... asthma and cancer and altered prostate and neurological development. ... restrict BPA,s use, and the public was pressuring retailers ...
Cached Biology News:Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 3Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 2Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 3BPA substitute could spell trouble 2
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
Applications: Western blotting ...
...
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: